What Are the Challenges in Targeting FGF Signaling?
Despite the potential, targeting FGF signaling in cancer therapy faces several challenges:
- Resistance: Tumors can develop resistance to FGFR inhibitors through secondary mutations or bypass pathways. - Specificity: Achieving specificity without affecting normal tissues that also rely on FGF signaling for physiological functions. - Toxicity: Managing adverse effects that arise from disrupting FGF signaling in normal cells.
